Key Highlights
- Net loss per share was USD 0.15; the estimate was a USD 0.1336 loss.
- Net loss was USD 21.83 million, against USD 22.14 million.
- Research and development expense was USD 17.46 million, against USD 17.44 million.
- Cash stood at USD 35.45 million and short-term investments at USD 111.75 million.
ALX Oncology (NASDAQ:ALXO) lost USD 21.83 million in the third quarter of 2026, against USD 22.14 million in the third quarter of 2025. The loss per share was USD 0.15, against USD 0.41 a year earlier and an estimated loss of USD 0.1336.
Spending and Interest Lines
Research and development expense was USD 17.46 million, against USD 17.44 million, and general and administrative expense was USD 5.48 million, against USD 5.09 million. Total operating expenses, which equal the loss from operations, were USD 22.95 million, against USD 22.53 million.
Interest income was USD 1.38 million, against USD 0.80 million, while interest expense was USD 0.23 million, against USD 0.41 million.
Nine Months to September 30
Across the nine months ended September 30, 2026, the net loss was USD 57.72 million, against USD 78.85 million, and the loss per share was USD 0.45, against USD 1.48. Research and Development expense was USD 44.21 million, against USD 59.35 million, and general and administrative expense was USD 15.98 million, against USD 18.47 million. Total operating expenses were USD 59.95 million, against USD 81.00 million.
Balance Sheet, Pipeline and Financing Terms
At September 30, 2026, cash and cash equivalents were USD 35.45 million, against USD 16.37 million at December 31, 2025, and short-term investments were USD 111.75 million, against USD 28.42 million. Prepaid expenses and other current Assets were USD 5.66 million, against USD 5.94 million, and total current assets were USD 152.87 million, against USD 50.73 million.
The company has two clinical-stage product candidates. One is evorpacept, a CD47 blocker, and the other is ALX2004, an antibody-drug conjugate aimed at EGFR that entered a Phase 1 trial in August 2025. In the Phase 2 ASPEN-09-Breast trial, evorpacept is paired with trastuzumab and chemotherapy for metastatic HER2-positive breast cancer. It is also in clinical studies alongside other targeted anti-cancer antibodies.
The HSBC Loan agreement allows a further USD 20.0 million in two tranches, the filing says. USD 10.0 million becomes available on milestones tied to the clinical development of evorpacept and ALX2004, and the other USD 10.0 million rests on the lender's judgment alone. The company also describes an at-the-market Equity program with sales agents, under which it may sell common stock for aggregate gross proceeds of up to USD 150.0 million.
Total assets were USD 154.67 million, against USD 59.05 million, and total liabilities were USD 28.82 million, against USD 33.07 million. The non-current term loan was USD 9.74 million, against USD 4.53 million, and total stockholders' equity was USD 125.85 million, against USD 25.98 million. The accumulated Deficit was USD 780.54 million, against USD 722.82 million.
The Quarter in Brief
ALX Oncology reported a net loss of USD 21.83 million and a loss of USD 0.15 per share. Cash and cash equivalents were USD 35.45 million at September 30, 2026.





_11_19_2026_19_57_40_035532.jpg)
Please wait processing your request...